173 results on '"Day, John"'
Search Results
2. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes in patients with and without structural heart disease.
- Author
-
Sessions AJ, May HT, Crandall BG, Day JD, Cutler MJ, Groh CA, Navaravong L, Ranjan R, Steinberg BA, and J Bunch T
- Subjects
- Humans, Treatment Outcome, Atrial Fibrillation surgery, Heart Failure, Stroke, Catheter Ablation adverse effects
- Abstract
Introduction: Atrial Fibrillation (AF) is a common arrhythmia often comorbid with systolic or diastolic heart failure (HF). Catheter ablation is a more effective treatment for AF with concurrent left ventricular dysfunction, however, the optimal timing of use in these patients is unknown., Methods: All patients that received a catheter ablation for AF(n = 9979) with 1 year of follow-up within the Intermountain Healthcare system were included. Patients with were identified by the presence of structural disease by ejection fraction (EF): EF ≤ 35% (n = 1024) and EF > 35% (n = 8955). Recursive partitioning categories were used to separate patients into clinically meaningful strata based upon time from initial AF diagnosis until ablation: 30-180(n = 2689), 2:181-545(n = 1747), 3:546-1825(n = 2941), and 4:>1825(n = 2602) days., Results: The mean days from AF diagnosis to first ablation was 3.5 ± 3.8 years (EF > 35%: 3.5 ± 3.8 years, EF ≤ 35%: 3.4 ± 3.8 years, p = .66). In the EF > 35% group, delays in treatment (181-545 vs. 30-180, 546-1825 vs. 30-180, >1825 vs. 30-180 days) increased the risk of death with a hazard ratio (HR) of 2.02(p < .0001), 2.62(p < .0001), and 4.39(p < .0001) respectively with significant risks for HF hospitalization (HR:1.44-3.69), stroke (HR:1.11-2.14), and AF recurrence (HR:1.42-1.81). In patients with an EF ≤ 35%, treatment delays also significantly increased risk of death (HR 2.07-3.77) with similar trends in HF hospitalization (HR:1.63-1.09) and AF recurrence (HR:0.79-1.24)., Conclusion: Delays in catheter ablation for AF resulted in increased all-cause mortality in all patients with differential impact observed on HF hospitalization, stroke, and AF recurrence risks by baseline EF. These data favor earlier use of ablation for AF in patients with and without structural heart disease., (© 2023 Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
3. Atrial cardiomyopathy: from cell to bedside.
- Author
-
Li M, Ning Y, Tse G, Saguner AM, Wei M, Day JD, Luo G, and Li G
- Subjects
- Humans, Heart Atria, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Embolic Stroke complications, Stroke etiology, Cardiomyopathies etiology, Cardiomyopathies complications
- Abstract
Atrial cardiomyopathy refers to structural and electrical remodelling of the atria, which can lead to impaired mechanical function. While historical studies have implicated atrial fibrillation as the leading cause of cardioembolic stroke, atrial cardiomyopathy may be an important, underestimated contributor. To date, the relationship between atrial cardiomyopathy, atrial fibrillation, and cardioembolic stroke remains obscure. This review summarizes the pathogenesis of atrial cardiomyopathy, with a special focus on neurohormonal and inflammatory mechanisms, as well as the role of adipose tissue, especially epicardial fat in atrial remodelling. It reviews the current evidence implicating atrial cardiomyopathy as a cause of embolic stroke, with atrial fibrillation as a lagging marker of an increased thrombogenic atrial substrate. Finally, it discusses the potential of antithrombotic therapy in embolic stroke with undetermined source and appraises the available diagnostic techniques for atrial cardiomyopathy, including imaging techniques such as echocardiography, computed tomography, and magnetic resonance imaging as well as electroanatomic mapping, electrocardiogram, biomarkers, and genetic testing. More prospective studies are needed to define the relationship between atrial cardiomyopathy, atrial fibrillation, and embolic stroke and to establish a prompt diagnosis and specific treatment strategies in these patients with atrial cardiomyopathy for the secondary and even primary prevention of embolic stroke., (© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2022
- Full Text
- View/download PDF
4. Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease.
- Author
-
Burnham TS, May HT, Bair TL, Anderson JA, Crandall BG, Cutler MJ, Day JD, Freedman RA, Knowlton KU, Muhlestein JB, Navaravong L, Ranjan RA, Steinberg BA, and Bunch TJ
- Subjects
- Anti-Arrhythmia Agents therapeutic use, Flecainide therapeutic use, Humans, Prospective Studies, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Coronary Artery Disease complications, Coronary Artery Disease drug therapy
- Abstract
Background: Class 1C antiarrhythmic drugs (AAD) have been associated with harm in patients treated for ventricular arrhythmias with a prior myocardial infarction. Consensus guidelines have advocated that these drugs not be used in patients with stable coronary artery disease (CAD). However, long-term data are lacking to know if unique risks exist when these drugs are used for atrial fibrillation (AF) in patients with CAD without a prior myocardial infarction., Methods: In 24,315 patients treated with the initiation of AADs, two populations were evaluated: (1) propensity-matched AF patients with CAD were created based upon AAD class (flecainide, n = 1,114, vs class-3 AAD, n = 1,114) and (2) AF patients who had undergone a percutaneous coronary intervention or coronary artery bypass graft (flecainide, n = 150, and class-3 AAD, n = 1,453). Outcomes at 3 years for mortality, heart failure (HF) hospitalization, ventricular tachycardia (VT), and MACE were compared between the groups., Results: At 3 years, mortality (9.1% vs 19.3%, P < .0001), HF hospitalization (12.5% vs 18.3%, P < .0001), MACE (22.9% vs 36.6%, P < .0001), and VT (5.8% vs 8.5%, P = .02) rates were significantly lower in the flecainide group for population 1. In population 2, adverse event rates were also lower, although not significantly, in the flecainide compared to the class-3 AAD group for mortality (20.9% vs 25.8%, P = .26), HF hospitalization (24.5% vs 26.1%, P = .73), VT (10.9% vs 14.7%, P = .28) and MACE (44.5% vs 49.5%, P = .32)., Conclusions: Flecainide in select patients with stable CAD for AF has a favorable safety profile compared to class-3 AADs. These data suggest the need for prospective trials of flecainide in AF patients with CAD to determine if the current guideline-recommended exclusion is warranted., Competing Interests: Declaration of Competing Interest Benjamin Steinberg receives support from the National Heart, Lung, And Blood Institute of the National Institutes of Health (#K23HL143156), and reports research support from Abbott, Boston Scientific, and Janssen; and consulting to Janssen, AltaThera, Merit Medical, and Bayer; and speaking for NACCME (funded by Sanofi). Ravi Ranjan is supported by NIH R01 HL142913. Ravi Fanjan also has or has had recent research grants from Biosense Webster and Abbott and is a consultant to Abbott and Biosense Webster. John Day has consulted with Abbott Medical and Boston Scientific. T. Jared Bunch MD has received research grants: Boehringer Ingelheim, Boston Scientific, Altathera. All others report no conflicts of interest relevant to this study., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
5. Rates and Anticoagulation Treatment of Known Atrial Fibrillation in Patients with Acute Ischemic Stroke: A Real-World Study.
- Author
-
Yuan H, An J, Zhang Q, Zhang X, Sun M, Fan T, Cheng Y, Wei M, Tse G, Waintraub X, Li Y, Day JD, Gao F, Luo G, and Li G
- Subjects
- Administration, Oral, Anticoagulants therapeutic use, China epidemiology, Female, Humans, Male, Risk Factors, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Brain Ischemia drug therapy, Brain Ischemia epidemiology, Ischemic Stroke, Stroke drug therapy, Stroke epidemiology
- Abstract
Introduction: Known atrial fibrillation (AF) rate and appropriate prescription of oral anticoagulants (OACs) in acute ischemic stroke (AIS) patients with AF in China are not as well known as in Western countries., Methods: Known AF and unknown AF, rate and adequacy of OACs use of AIS patients with AF attending five hospitals from April 2018 to August 2019 in the northwest region of China were investigated., Results: A total of 344 patients were enrolled. Of these, 237 (AF-known group; 237/344, 68.9%) and 107 patients (AF-unknown group; 107/344, 31.1%) were diagnosed with AF before and after AIS during this hospitalization, respectively. In the AF-known group with echocardiography results (178 patients, including 103 female and 75 male patients), 154 of overall, 88 of female and 66 of male patients, respectively, were indicated to be taking OACs. However, the actual OACs proportion was much lower [overall (30.5%, 47/154); female (31.8%, 28/88) and male (28.8%, 19/66) patients] than indicated. Only one female patient met the guideline-based criteria for OACs. As for patients diagnosed with massive cerebral infraction (MCI; 43.0%, 148/344), the known AF rate was 65.5% (97/148). Among the MCI patients in the AF-known group with echocardiography results (61 patients), 50 patients had an OACs indication. However, only 22.0% (11/50) of these patients took OACs, and none met the guideline-based criteria for OACs., Conclusions: This study revealed a low known AF rate, low OACs use rate and low rate of meeting the guideline-based criteria for OACs in AIS patients with AF in the northwest region of China. These findings indicated the importance of AF as a public health problem in China.
- Published
- 2020
- Full Text
- View/download PDF
6. Procedural Patterns and Safety of Atrial Fibrillation Ablation: Findings From Get With The Guidelines-Atrial Fibrillation.
- Author
-
Loring Z, Holmes DN, Matsouaka RA, Curtis AB, Day JD, Desai N, Ellenbogen KA, Feld GK, Fonarow GC, Frankel DS, Hurwitz JL, Knight BP, Joglar JA, Russo AM, Sidhu MS, Turakhia MP, Lewis WR, and Piccini JP
- Subjects
- Aged, Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Catheter Ablation adverse effects, Cryosurgery adverse effects, Female, Guideline Adherence trends, Humans, Male, Middle Aged, Postoperative Complications etiology, Practice Guidelines as Topic, Pulmonary Veins physiopathology, Registries, Time Factors, Treatment Outcome, United States, Atrial Fibrillation surgery, Catheter Ablation trends, Cryosurgery trends, Practice Patterns, Physicians' trends, Pulmonary Veins surgery
- Abstract
Background: Catheter ablation is an increasingly used treatment for symptomatic atrial fibrillation (AF). However, there are limited prospective, nationwide data on patient selection and procedural characteristics. This study describes patient characteristics, techniques, treatment patterns, and safety outcomes of patients undergoing AF ablation., Methods: A total of 3139 patients undergoing AF ablation between 2016 and 2018 in the Get With The Guidelines-Atrial Fibrillation registry from 24 US centers were included. Patient demographics, medical history, procedural details, and complications were abstracted. Differences between paroxysmal and patients with persistent AF were compared using Pearson χ
2 and Wilcoxon rank-sum tests., Results: Patients undergoing AF ablation were predominantly male (63.9%) and White (93.2%) with a median age of 65. Hypertension was the most common comorbidity (67.6%), and patients with persistent AF had more comorbidities than patients with paroxysmal AF. Drug refractory, paroxysmal AF was the most common ablation indication (class I, 53.6%) followed by drug refractory, persistent AF (class I, 41.8%). Radiofrequency ablation with contact force sensing was the most common ablation modality (70.5%); 23.7% of patients underwent cryoballoon ablation. Pulmonary vein isolation was performed in 94.6% of de novo ablations; the most common adjunctive lesions included left atrial roof or posterior/inferior lines, and cavotricuspid isthmus ablation. Complications were uncommon (5.1%) and were life-threatening in 0.7% of cases., Conclusions: More than 98% of AF ablations among participating sites are performed for class I or class IIA indications. Contact force-guided radiofrequency ablation is the dominant technique and pulmonary vein isolation the principal lesion set. In-hospital complications are uncommon and rarely life-threatening.- Published
- 2020
- Full Text
- View/download PDF
7. Long-term outcomes after low power, slower movement versus high power, faster movement irrigated-tip catheter ablation for atrial fibrillation.
- Author
-
Bunch TJ, May HT, Bair TL, Crandall BG, Cutler MJ, Mallender C, Weiss JP, Osborn JS, and Day JD
- Subjects
- Aged, Equipment Design, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Time Factors, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation instrumentation
- Abstract
Background: High power, shorter duration (HPSD) ablation strategies have been advocated to increase efficacy and minimize posterior wall deep tissue thermal injury during atrial fibrillation (AF) ablation., Objective: The purpose of this study was to determine the long-term outcomes of arrhythmia-free survival from AF and atrial flutter (AFL) between HPSD and low power, longer duration (LPLD) ablation strategies., Methods: Of a total of 1333 first time AF ablation procedures with 3 years of follow-up, propensity-matched populations for baseline risk factors were created, comprising 402 patients treated with LPLD ablation (30 W for 5 seconds: posterior wall; 30 W for 10-20 seconds: anterior wall) and 402 patients treated with HPSD ablation (50 W for 2-3 seconds: posterior wall; 50 W for 5-15 seconds: anterior wall). AF/AFL outcomes after a 90-day blanking period were assessed., Results: HPSD ablation was associated with shorter procedure and fluoroscopy times (P < .0001 for both). The recurrence of AF at 1 year (12.9% vs 16.2%; P = .19) and 3 years (26.5% vs 30.7%; P = .23) was similar between LPLD and HPSD groups. AFL was higher at 1 year (7.2% vs 11.2%; P = .03) and 3 years (16.1% vs 21.8%; P = .06; P = .04 after multivariate adjustment) with HPSD ablation. Patients who underwent an LPLD approach had lower rates of need for repeat ablation (21% vs 30%; P = .002)., Conclusion: Long-term freedom from AF rates were not significantly different between both approaches. An HPSD ablation strategy compared with an LPLD approach was associated with an increased risk of AFL and need for repeat ablation but with lowered procedure times., (Copyright © 2019 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
8. Stroke and dementia risk in patients with and without atrial fibrillation and carotid arterial disease.
- Author
-
Bunch TJ, Bair TL, Crandall BG, Cutler MJ, Day JD, Graves KG, Jacobs V, Mallender C, Osborn JS, Weiss JP, and May HT
- Subjects
- Aged, Atrial Fibrillation epidemiology, Carotid Artery Diseases epidemiology, Dementia epidemiology, Female, Follow-Up Studies, Humans, Incidence, Male, Risk Factors, Stroke epidemiology, United States epidemiology, Atrial Fibrillation complications, Carotid Artery Diseases complications, Dementia etiology, Risk Assessment methods, Stroke etiology
- Abstract
Background: Patients with carotid arterial disease (CD) with and without atrial fibrillation (AF) are at risk of stroke. Patients with AF are at a higher risk of stroke and dementia., Objectives: We sought to understand the risks of stroke, transient ischemic attack (TIA), and dementia in patients with and without AF and CD or a combination of both as well as to determine whether therapies for each disease may influence risks., Methods: A total of 11,572 patients were included in 4 groups, with 2893 patients populating each group (1: no AF or CD; 2: AF, no CD; 3: CD and no AF; 4: AF and CD) and matched for age, sex, and comorbidities. Long-term outcomes of stroke/TIA and dementia were assessed. Subset analyses of these outcomes were performed in patients with CD treated with revascularization and in patients with AF treated with ablation., Results: CD increased the risk of stroke/TIA (hazard ratio [HR] 2.74; P < .0001) and dementia (HR 1.44; P < .0001). Similarly, AF increased the risk of stroke/TIA (HR 2.08; P < .0001) and dementia (HR 1.30; P = .004). The coexistence of AF and CD further augmented the risk of both end points. CD revascularization was associated with a decreased risk of dementia (HR 0.47; P < .0001) but not stroke. Ablation of AF improved outcomes of stroke/TIA (HR 0.55; P = .002), particularly in those with CD (HR 0.36; P < .0001), and was associated with a reduced risk of dementia (HR 0.51; P = .04)., Conclusion: CD and AF augment risk of stroke/TIA and dementia in the general population, and the coexistence of both diseases is additive in risk. Ablation of AF was associated with lower risk, the magnitude of which was greater in those with CD., (Copyright © 2019 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
9. Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study.
- Author
-
Bunch TJ, Jacobs V, May H, Stevens SM, Crandall B, Cutler M, Day JD, Mallender C, Olson J, Osborn J, Weiss JP, and Woller SC
- Subjects
- Aged, Anticoagulants adverse effects, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Cognitive Dysfunction diagnosis, Cognitive Dysfunction epidemiology, Cognitive Dysfunction psychology, Dabigatran adverse effects, Dementia diagnosis, Dementia epidemiology, Dementia psychology, Female, Humans, Incidence, International Normalized Ratio, Male, Prospective Studies, Randomized Controlled Trials as Topic, Risk Factors, Time Factors, Treatment Outcome, Warfarin adverse effects, Anticoagulants administration & dosage, Atrial Fibrillation drug therapy, Cognition drug effects, Cognitive Dysfunction prevention & control, Dabigatran administration & dosage, Dementia prevention & control, Warfarin administration & dosage
- Abstract
Atrial fibrillation (AF) is associated with a risk for cognitive impairment and dementia, which is more pronounced in patients with a history of clinical stroke. Observational trials suggest that the implementation and quality of long-term anticoagulation impact dementia risk. Emerging evidence suggests that direct oral anticoagulants may improve long-term risk of dementia in AF patients. This manuscript describes the rational and trial design of the the Cognitive Decline and Dementia in Atrial Fibrillation Patients (CAF) Trial. CAF investigates if AF patients randomized to dabigatran etexilate will have long-term higher cognition scores and lower rates of dementia compared in the long term to dose-adjusted warfarin (International Normalized Ratio [INR]: 2.0-3.0). As of 27 February 2019, a total of 120 subjects will be enrolled at one investigational site in the United States and will be followed for 2 years after study enrollment. To date, 97 have been enrolled. The average age is 74.2 years, 53% are male, and 9% had a prior stroke. In this Vanguard study, patients will be followed for 2 years after study enrollment. These prospective, randomized data will inform the understanding of two anticoagulants in AF patients as it relates to risk of cognitive decline and dementia. Cranial imaging and biomarkers collected will assist in understanding mechanisms of brain injury., (© 2019 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
10. Mechanisms of Improved Mortality Following Ablation: Does Ablation Restore Beta-Blocker Benefit in Atrial Fibrillation/Heart Failure?
- Author
-
Bunch TJ, May HT, Afshar K, Alharethi R, and Day JD
- Subjects
- Atrial Fibrillation physiopathology, Atrial Fibrillation surgery, Comorbidity, Global Health, Heart Failure physiopathology, Humans, Postoperative Period, Survival Rate trends, Adrenergic beta-Antagonists therapeutic use, Atrial Fibrillation mortality, Catheter Ablation, Heart Failure mortality, Stroke Volume physiology, Ventricular Function, Left physiology
- Abstract
Observational trials have shown that atrial fibrillation ablation favorably impacts long-term outcomes in systolic heart failure. These outcomes have been confirmed by randomized prospective trials highlighting the favorable impact of ablation on left ventricular function and remodeling, risk of heart failure hospitalization, and mortality. Ablation along with established heart failure medications is new and supported conceptually by the value of restoring sinus rhythm, avoiding long-term antiarrhythmic drugs, and minimizing drug-drug interactions. Observational data suggest a potential long-term benefit of beta-blockers with ablation that becomes augmented as follow-up is extended from 1 to 5 years., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
11. Low complication rates using high power (45-50 W) for short duration for atrial fibrillation ablations.
- Author
-
Winkle RA, Mohanty S, Patrawala RA, Mead RH, Kong MH, Engel G, Salcedo J, Trivedi CG, Gianni C, Jais P, Natale A, and Day JD
- Subjects
- Burns, Electric etiology, Burns, Electric prevention & control, Female, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Pulmonary Veins surgery, Time Factors, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Catheter Ablation methods, Intraoperative Complications etiology, Intraoperative Complications prevention & control, Postoperative Complications diagnosis, Postoperative Complications etiology, Postoperative Complications prevention & control, Radio Waves adverse effects
- Abstract
Background: Many centers use radiofrequency (RF) energy at 25-35 W for 30-60 seconds. There is a safety concern about using higher power, especially on the posterior wall., Objective: The purpose of this study was to examine complication rates for atrial fibrillation (AF) ablations performed with high-power, short-duration RF energy., Methods: We examined the complication rates of 4 experienced centers performing AF ablations at RF powers from 45-50 W for 2-15 seconds per lesion. In total, 13,974 ablations were performed in 10,284 patients. On the posterior wall, 11,436 ablations used 45-50 W for 2-10 seconds, and 2538 ablations used power reduced to 35 W for 20 seconds. Esophageal temperature monitoring was used in 13,858 (99.2%)., Results: Demographics were age 64 ± 11 years, male 68%, left atrial size 4.4 ± 0.7 cm, paroxysmal AF 37%, persistent AF 42%, longstanding AF 20%, antiarrhythmic drugs failed 1.4 ± 0.7, hypertension 54%, diabetes 15%, previous cerebrovascular accident/transient ischemic attack 7%, and CHA
2 DS2 -VASc score 2.1 ± 1.4. Procedural time was 116 ± 41 minutes. Complications were death in 2 (0.014%; 1 due to stroke and 1 due to atrioesophageal fistula), pericardial tamponade in 33 (0.24%; 26 tapped, 7 surgical), strokes <48 hours in 6 (0.043%), strokes 48 hours-30 days in 6 (0.043%), pulmonary vein stenosis requiring intervention in 2 (0.014%), phrenic nerve paralysis in 2 (0.014%; both resolved), steam pops 2 (0.014%) without complications, and catheter char 0 (0.00%). There was 1 atrioesophageal fistula in 11,436 ablations using power 45-50 W on the posterior wall and 3 in 2538 ablated with 35 W on the posterior wall (P = .021), although 2 of the 3 had no esophageal monitoring during a fluoroless procedure., Conclusion: AF ablations can be performed at 45-50 W for short durations with very low complication rates. High-power, short-duration ablations have the potential to shorten procedural and total RF times and create more localized and durable lesions., (Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
12. The Impact of Gender on Atrial Fibrillation Incidence and Progression to Dementia.
- Author
-
Golive A, May HT, Bair TL, Jacobs V, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Weiss JP, and Bunch TJ
- Subjects
- Age Factors, Cohort Studies, Diabetes Mellitus epidemiology, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Risk, Sex Factors, Stroke epidemiology, Utah epidemiology, Atrial Fibrillation epidemiology, Dementia epidemiology, Disease Progression
- Abstract
There are a paucity of data regarding the role of gender and atrial fibrillation (AF) on cognitive decline and incidence of dementia. Such data may provide insight into the disproportionate incidence of dementia in women and may help identify high-risk characteristics to target for prevention. We examined patients who underwent coronary angiography at an Intermountain Healthcare Medical Center and enrolled in a prospective cardiovascular database. To be included, patients could not have a previous diagnosis of AF or dementia and had to have 5years of follow-up. Endpoints included incident AF and dementia. Study cohort consisted of 35,608 patients without a previous history of AF or dementia, with 14,377 (40.4%) being woman. Women had lower rates of hypertension, diabetes, coronary artery disease, and prior myocardial infarction, but higher rates of prior stroke. Men had a higher incidence of 5-year and long-term AF. However, women trended toward a higher incidence of 5-year and long-term dementia and stroke compared with men. In all groups of patients with and without AF, prior stroke predicted cognitive decline. In patients without a history of or development of AF, diabetes significantly increased risk of dementia. Women have higher rates of dementia over time than men, driven by higher baseline stroke rates and nontraditional cardiovascular risk factors. The higher dementia rates were in the setting of lower AF rates. However, in both men and women who develop AF, dementia rates are increased and do not show gender-based differences in risk., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
13. Vagus nerve injury symptoms after catheter ablation for atrial fibrillation.
- Author
-
Jacobs V, May HT, Crandall BG, Ballantyne B, Chisum B, Johnson D, Graves KG, Cutler M, Day JD, Mallender C, Osborn JS, Weiss JP, and Bunch TJ
- Subjects
- Female, Humans, Male, Middle Aged, Quality of Life, Risk Factors, Surveys and Questionnaires, Atrial Fibrillation surgery, Radiofrequency Ablation adverse effects, Vagus Nerve Injuries etiology
- Abstract
Background: Vagus nerve injury during catheter ablation for atrial fibrillation can significantly impact quality of life and result in lingering gastrointestinal symptoms. This study was designed to define risk factors of vagus nerve injury, symptoms, prevalence, and temporal resolution., Methods: A total of 100 patients undergoing radiofrequency catheter ablation (RFCA) were enrolled and consented to participate in the study. Patients completed a 22-item questionnaire that included questions specific to vagus nerve injury symptomatology during their baseline visit and at 1 and 3 months post-RFCA., Results: The average age of the population was 63 ± 10.6 years and 68% were male. A total of 100 patients completed their baseline questionnaire (90 patients completed the 1-month questionnaires and 85 patients completed the 3-month questionnaires). Symptoms rated as moderate were prevalent at baseline (trouble swallowing 13%, bloating 26%, feeling full 20%), and increased in all categories analyzed at 1 month and with the exception of trouble swallowing returned to the preablation percentages at 3 months (heartburn 22.4%, trouble swallowing 18.8%, bloating 16.5%, nausea 8.2%, vomiting 3.5%, constipation 18.8%, diarrhea 16.4%, feeling full 15.3%). Severe rated symptoms of trouble swallowing (2-5.5%), bloating (5-7.6%), and early satiety (5-9.8%) increased at 1 month and bloating and early satiety percentages remained approximately two times higher at 3 months (trouble swallowing 2.4%, bloating 8.2%, early satiety 7.1%)., Conclusion: The majority of symptoms were resolved by 3 months, although those patients who rate bloating and early satiety at a severe rating may have persistent symptoms., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
14. Five-year impact of catheter ablation for atrial fibrillation in patients with a prior history of stroke.
- Author
-
Bunch TJ, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Jacobs V, Mallender C, Osborn JS, and Weiss JP
- Subjects
- Action Potentials, Aged, Aged, 80 and over, Anti-Arrhythmia Agents therapeutic use, Anticoagulants therapeutic use, Atrial Fibrillation diagnosis, Atrial Fibrillation mortality, Atrial Fibrillation physiopathology, Case-Control Studies, Databases, Factual, Female, Heart Failure etiology, Heart Failure physiopathology, Heart Rate, Humans, Male, Middle Aged, Recurrence, Risk Assessment, Risk Factors, Stroke diagnosis, Stroke mortality, Stroke physiopathology, Time Factors, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Stroke prevention & control
- Abstract
Background: Catheter ablation of atrial fibrillation (AF) is an established therapeutic rhythm approach. Patients with a prior history of a stroke (CVA) represent a unique high-risk population for recurrent thromboembolic events. The role of antiarrhythmic treatment on the natural history of stroke recurrence in these patients is not fully understood., Methods: Three patient groups with a prior CVA and 5 years of follow-up were matched 1:3:3 by propensity score (±0.01): AF ablation patients receiving their first ablation (n = 139), AF patients that did not receive an ablation (n = 416), and CVA patients without clinical AF (n = 416). Prior CVA was determined by medical chart review. Patients were followed for outcomes of recurrent CVA, heart failure, and death., Results: The average age of the population was 69 ± 11 years and 51% male. AF ablation patients had higher rates of hypertension and heart failure (P < 0.0001), but diabetes prevalence was similar between the groups (P = 0.5). Note that 5-year risk of CVA (HR = 2.26, P < 0.0001) and death (HR = 2.43, P < 0.0001) were higher in the AF, no ablation group compared those that were ablated. When comparing AF, ablation to no AF patients, there was not a significant difference in 5-year risk of for CVA (HR = 0.82, P = 0.39) and death (HR = 0.92, P = 0.70); however, heart failure risk was increased (HR = 3.08, P = 0.001)., Conclusion: In patients with AF and a prior CVA, patients undergoing ablation have lower rates of recurrent stroke compared to AF patients not ablated. Although the full mechanisms of benefit are unknown, as CVA rates are similar to patients without AF these data are suggestive of a potential altering of the natural history of disease progression., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
15. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.
- Author
-
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, and Yamane T
- Subjects
- Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Cardiac Catheterization adverse effects, Catheter Ablation adverse effects, Consensus, Cryosurgery adverse effects, Humans, Risk Factors, Treatment Outcome, Atrial Fibrillation surgery, Cardiac Catheterization standards, Catheter Ablation standards, Cryosurgery standards
- Published
- 2018
- Full Text
- View/download PDF
16. Reply: Are Rotors Markers of Substrate or a Mechanism of Perpetuation of Atrial Fibrillation? Increasing Data for Rotational Drivers of Human AF.
- Author
-
Zaman JAB, Swarup V, Daubert JP, Day JD, Hummel J, Schricker AA, Krummen DE, Viswanathan MN, Park S, Narayan SM, and Miller JM
- Subjects
- Body Surface Potential Mapping, Heart Conduction System, Humans, Atrial Fibrillation
- Published
- 2017
- Full Text
- View/download PDF
17. Long-term aspirin does not lower risk of stroke and increases bleeding risk in low-risk atrial fibrillation ablation patients.
- Author
-
Jacobs V, May HT, Bair TL, Crandall BG, Cutler DO MJ, Day JD, Mallender C, Osborn JS, Weiss JP, and Bunch TJ
- Subjects
- Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Atrial Fibrillation therapy, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage chemically induced, Humans, Male, Middle Aged, Retrospective Studies, Stroke prevention & control, Aspirin administration & dosage, Aspirin adverse effects, Atrial Fibrillation epidemiology, Catheter Ablation trends, Hemorrhage epidemiology, Stroke epidemiology
- Abstract
Background: Stroke risk is a significant concern in patients with atrial fibrillation (AF). Low stroke risk patients (CHADS
2 VASc 0-2) are often treated long-term with aspirin after catheter ablation. Defining the long-term risks versus benefits of aspirin therapy, after an ablation, is essential to validate this common clinical approach., Methods: A total of 4,124 AF ablation patients undergoing their index ablation were included in this retrospective observational study. We compared 1- and 3-year outcomes for cerebrovascular accident (CVA), transient ischemic attack (TIA), gastrointestinal (GI) bleeding, genitourinary (GU) bleeding, any bleeding, and AF recurrence among patients receiving: none, aspirin, or warfarin as long-term therapies., Results: Patient distribution by CHADS2 VASc scores was as follows: 0: 1,143 (28%), 1: 1,588 (39%), and 2: 1,393 (34%). Significantly higher incidents of: female gender, hypertension, diabetes mellitus, heart failure, and vascular disease were seen with higher CHADS2 VASc scores (P < 0.0001 for all). At 3 years, 238 (5.9%) patients were on warfarin, 743 (18.6) on aspirin, and 3,013 (75.5%) on no therapy; with occurrences of CVA/TIA (1.4%, 3.0%, 3.9%, P < 0.0001, respectively), GI bleeding (0.8%, 1.9%, 1.1%, P = 0.06, respectively), and GU bleeding (1.7%, 2.8%, 2.1%, P = 0.008, respectively) that increased with advancing CHA2 DS2 VASc score. There was a significantly increased risk for both CVA/TIA with aspirin therapy, when compared to no therapy or warfarin therapy in general, and across all CHA2 DS2 VASc scores., Conclusions: After catheter ablation, low risk patients do not benefit from long-term aspirin therapy, but are at risk for higher rates of bleeding when compared to no therapy or warfarin., (© 2017 Wiley Periodicals, Inc.)- Published
- 2017
- Full Text
- View/download PDF
18. Safety of catheter ablation of atrial fibrillation using fiber optic-based contact force sensing.
- Author
-
Mansour M, Lakkireddy D, Packer D, Day JD, Mahapatra S, Brunner K, Reddy V, and Natale A
- Subjects
- Equipment Design, Europe, Female, Follow-Up Studies, Humans, Male, Retrospective Studies, Risk Factors, Treatment Outcome, United States, Atrial Fibrillation surgery, Catheter Ablation instrumentation, Catheters, Pulmonary Veins surgery
- Abstract
Background: While the body of evidence showing the benefit of contact force (CF)-sensing catheters in improving atrial fibrillation ablation success rate is growing, real-world safety data of this technology are limited., Objective: The aim of this study was to report the complication rate in patients undergoing ablation using a specific CF-sensing catheter (TactiCath Quartz CF ablation catheter, Abbott, St. Paul, MN) in a large worldwide database., Methods: User-reported adverse event data from January 1, 2014 to December 31, 2015 were reviewed for the ablation catheter. These adverse events included cardiac perforation, cerebrovascular accident, atrioesophageal (AE) fistula, steam pop, and death. Rates of these adverse events, including geographic and temporal relationships, were calculated., Results: Adverse events were reported in 178 of 41,709 patients (adverse event rate 0.427%). Adverse events included 117 cardiac perforations (0.281%), 5 cerebrovascular accidents (0.012%), 10 AE fistulas (0.024%), 53 audible steam pops (0.127%), and 13 deaths (0.031%). The total event rate in European countries was 0.53% vs 0.38% in the United States (P = .0082). The AE fistula event rate peaked in late 2014 and early 2015 at 0.06% and decreased over time to a steady-state 0.01%, corresponding to the initial US release, subsequent increased use, and training on the manufacturer recommended settings., Conclusion: Complication rates while using the TactiCath CF ablation catheter appear to decrease with training and experience. The major complication rate associated with this technology is low in the context of similar reports of conventional radiofrequency catheters., (Copyright © 2017 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
19. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary.
- Author
-
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Wyn Davies D, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, and Yamane T
- Subjects
- Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Consensus, Humans, Risk Factors, Atrial Fibrillation surgery, Cardiac Surgical Procedures standards, Catheter Ablation standards
- Published
- 2017
- Full Text
- View/download PDF
20. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.
- Author
-
Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, and Yamane T
- Subjects
- Catheter Ablation standards, Humans, Ablation Techniques standards, Atrial Fibrillation surgery, Cardiology, Consensus Development Conferences as Topic, Heart Conduction System surgery, Societies, Medical
- Published
- 2017
- Full Text
- View/download PDF
21. Risk Factor Management and Atrial Fibrillation Clinics: Saving the Best for Last?
- Author
-
Mahajan R, Pathak RK, Thiyagarajah A, Lau DH, Marchlinski FE, Dixit S, Day JD, Hendriks JML, Carrington M, Kalman JM, and Sanders P
- Subjects
- Global Health, Humans, Morbidity trends, Risk Factors, Survival Rate trends, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Atrial Fibrillation physiopathology, Risk Management methods
- Abstract
Atrial fibrillation (AF) is a leading cause of cardiovascular morbidity and mortality worldwide. Management of AF is a complex process involving: 1) the prevention of thromboembolic complications with anticoagulation; 2) rhythm control; and 3) the detection and treatment of underlying heart disease. However, cardiometabolic risk factors, such as obesity, hypertension, diabetes mellitus, and obstructive sleep apnoea, have been proposed as contributors to the expanding epidemic of atrial fibrillation (AF). Thus, a fourth pillar of AF care would include aggressive targeting of interdependent, modifiable cardiovascular risk factors as part of an integrated care model. Such risk factor management could retard and reverse the pathological processes underlying AF and reduce AF burden., (Crown Copyright © 2017. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
22. The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.
- Author
-
Golive A, May HT, Bair TL, Jacobs V, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, and Bunch TJ
- Subjects
- Aged, Atrial Fibrillation complications, Atrial Fibrillation mortality, Cause of Death trends, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage epidemiology, Humans, Incidence, Male, Middle Aged, Prognosis, Prospective Studies, Retrospective Studies, Risk Factors, Stroke epidemiology, Stroke etiology, Survival Rate trends, Time Factors, United States epidemiology, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Hemorrhage chemically induced, Platelet Aggregation Inhibitors therapeutic use, Risk Assessment, Stroke prevention & control
- Abstract
Among patients with atrial fibrillation (AF), the risk of stroke risk is a significant concern. CHADS
2 and CHA2 DS2 -VASc ≤2 scoring have been used to stratify patients into categories of risk. Without randomized, prospective data, the need and type of long-term antithrombotic medications for thromboembolism prevention in lower risk AF patients remains controversial. We sought to define the long-term impact of anticoagulant and antiplatelet therapy use in AF patients at low risk of stroke. A total of 56,764 patients diagnosed with AF and a CHADS2 score of 0 or 1, or CHA2 DS2 -VASc score of 0, 1, or 2 were studied. Antithrombotic therapy was defined as aspirin, clopidogrel (antiplatelet therapy), or warfarin monotherapy (anticoagulation) initiated within 6 months of AF diagnosis. End points included all-cause mortality, cerebrovascular accident, transient ischemic attack (TIA), and major bleed. The average age of the population was 67.0 ± 14.1 years and 56.6% were male. In total, 9,682 received aspirin, 1,802 received clopidogrel, 1,164 received warfarin, and 46,042 did not receive any antithrombotic therapy. Event rates differed between patients with a CHADS2 score of 0 and 1; 18.5% and 37.8% had died, 1.7% and 3.4% had a stroke, 2.2% and 3.2% had a TIA, and 14% and 12.5% had a major bleed, respectively (p <0.0001 for all). The rates of stroke, TIA, and major bleeding increased as antithrombotic therapy intensity increased from no therapy, to aspirin, to clopidogrel, and to warfarin (all p <0.0001). Similar outcomes were observed in low-risk CHA2 DS2 -VASc scores (0 to 2). In low-risk AF patients with a CHADS2 score of 0 to 1 or CHA2 DS2 -VASc score of 0 to 2, the use of aspirin, clopidogrel, and warfarin was not associated with lower stroke rates at 5 years compared with no therapy. However, the use of antithrombotic agents was associated with a significant risk of bleed., (Copyright © 2017 Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
23. Atrial fibrillation incrementally increases dementia risk across all CHADS 2 and CHA 2 DS 2 VASc strata in patients receiving long-term warfarin.
- Author
-
Graves KG, May HT, Jacobs V, Bair TL, Stevens SM, Woller SC, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Peter Weiss J, and Jared Bunch T
- Subjects
- Aged, Anticoagulants administration & dosage, Atrial Fibrillation complications, Dementia epidemiology, Female, Follow-Up Studies, Humans, Incidence, Male, Retrospective Studies, Risk Factors, Thromboembolism etiology, Time Factors, United States epidemiology, Atrial Fibrillation drug therapy, Dementia etiology, Risk Assessment, Thromboembolism prevention & control, Warfarin administration & dosage
- Abstract
Background: Patients with atrial fibrillation (AF) are at higher risk for developing dementia. Warfarin is a common therapy for the prevention of thromboembolism in AF, valve replacement, and thrombosis patients. The extent to which AF itself increases dementia risk remains unknown., Methods: A total 6030 patients with no history of dementia and chronically anticoagulated with warfarin were studied. Warfarin management was provided through a Clinical Pharmacy Anticoagulation Service. Patients were stratified by warfarin indication of AF (n=3015) and non-AF (n=3015) and matched by propensity score (±0.01). Patients were stratified by the congestive heart failure, hypertension, age >75 years, diabetes, stroke (CHADS
2 ) score calculated at the time of warfarin initiation and followed for incident dementia., Results: The average age of the AF cohort was 69.3±11.2 years, and 52.7% were male; average age of non-AF cohort was 69.3±10.9 years, and 51.5% were male. Increasing CHADS2 score was associated with increased dementia incidence, P trend=.004. When stratified by warfarin indication, AF patients had an increased risk of dementia incidence. After multivariable adjustment, AF patients continued to display a significantly increased risk of dementia when compared with non-AF patients across all CHADS2 scores strata., Conclusions: In patients receiving long-term warfarin therapy, dementia risk increased with increasing CHADS2 scores. However, the presence of AF was associated with higher rates of dementia across all CHADS2 score strata. These data suggest that AF contributes to the risk of dementia and that this risk is not solely attributable to anticoagulant use. Dementia may be an end manifestation of a systemic disease state, and AF likely contributes to its progression., (Copyright © 2017 Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
24. Recurrent Post-Ablation Paroxysmal Atrial Fibrillation Shares Substrates With Persistent Atrial Fibrillation : An 11-Center Study.
- Author
-
Zaman JAB, Baykaner T, Clopton P, Swarup V, Kowal RC, Daubert JP, Day JD, Hummel J, Schricker AA, Krummen DE, Mansour M, Tomassoni GF, Wheelan KR, Vishwanathan M, Park S, Wang PJ, Narayan SM, and Miller JM
- Subjects
- Humans, Recurrence, Reoperation, Treatment Outcome, Atrial Fibrillation pathology, Atrial Fibrillation surgery, Catheter Ablation methods
- Abstract
Introduction: The role of atrial fibrillation (AF) substrates is unclear in patients with paroxysmal AF (PAF) that recurs after pulmonary vein isolation (PVI). We hypothesized that patients with recurrent post-ablation (redo) PAF despite PVI have electrical substrates marked by rotors and focal sources, and structural substrates that resemble persistent AF more than patients with (de novo) PAF at first ablation., Methods: In 175 patients at 11 centers, we compared AF substrates in both atria using 64 pole-basket catheters and phase mapping, and indices of anatomical remodeling between patients with de novo or redo PAF and first ablation for persistent AF., Results: Sources were seen in all patients. More patients with de novo PAF (78.0%) had sources near PVs than patients with redo PAF (47.4%, p=0.005) or persistent AF (46.9%, p=0.001). The total number of sources per patient (p=0.444), and number of non-PV sources (p=0.701) were similar between groups, indicating that redo PAF patients had residual non-PV sources after elimination of PV sources by prior PVI. Structurally, left atrial size did not separate de novo from redo PAF (49.5±9.5 vs. 49.0±7.1mm, p=0.956) but was larger in patients with persistent AF (55.2±8.4mm, p=0.001)., Conclusions: Patients with paroxysmal AF despite prior PVI show electrical substrates that resemble persistent AF more closely than patients with paroxysmal AF at first ablation. Notably, these subgroups of paroxysmal AF are indistinguishable by structural indices. These data motivate studies of trigger versus substrate mechanisms for patients with recurrent paroxysmal AF after PVI.
- Published
- 2017
- Full Text
- View/download PDF
25. Long-term influence of body mass index on cardiovascular events after atrial fibrillation ablation.
- Author
-
Bunch TJ, May HT, Bair TL, Crandall BG, Cutler MJ, Jacobs V, Mallender C, Muhlestein JB, Osborn JS, Weiss JP, and Day JD
- Subjects
- Adult, Aged, Aged, 80 and over, Causality, Comorbidity, Female, Humans, Longitudinal Studies, Male, Middle Aged, Prevalence, Risk Factors, Survival Rate, Treatment Outcome, Utah epidemiology, Atrial Fibrillation mortality, Atrial Fibrillation surgery, Body Mass Index, Cardiovascular Diseases mortality, Catheter Ablation statistics & numerical data, Obesity mortality, Thinness mortality
- Abstract
Background: Catheter ablation of atrial fibrillation (AF) is an established therapeutic rhythm approach in symptomatic patients. Obesity is a dominant driver of AF recurrence after ablation. However, being both overweight and underweight drives long-term cardiac and general health risks. Long-term data are needed to understand the influence of body mass index (BMI) on outcomes after ablation in regard to arrhythmia recurrence and cardiovascular outcomes., Methods: All patients who underwent an index ablation with a BMI recorded and at least 3 years of follow-up were included (n = 1558). The group was separated and compared by index ablation BMI status (≤20, 21-25, 26-30, >30 kg/m(2)). Long-term outcomes included AF recurrence, stroke/TIA, heart failure (HF) hospitalization, and death., Results: Patients with advancing BMI status were more likely to be male and have hypertension, a smoking history, diabetes, HF, and a prior cardioversion. Patients with a BMI ≤20 were more likely to have a moderate-high congestive heart failure, hypertension, age >75, diabetes, stroke (CHADS2) score. At 3 years, recurrence rates of AF increased significantly with increasing BMI status (p = 0.02); paradoxically, there was a trend for increased stroke risk with decreasing BMI (p = 0.06). Long-term death rates tended to increase inversely with BMI status, and HF rates were greatest in the highest and lowest BMI groups., Conclusions: Lower weight at AF ablation lowers arrhythmia recurrence risk. However, AF ablation patients who are normal or underweight remain at high risk of other cardiovascular outcomes including increased stroke risk with less AF burden.
- Published
- 2016
- Full Text
- View/download PDF
26. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
- Author
-
Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Mallender C, Osborn JS, Stevens SM, Weiss JP, Woller SC, and Bunch TJ
- Subjects
- Aged, Aged, 80 and over, Antithrombins therapeutic use, Atrial Fibrillation complications, Dabigatran therapeutic use, Dementia epidemiology, Factor Xa Inhibitors therapeutic use, Female, Hemorrhage epidemiology, Humans, Ischemic Attack, Transient epidemiology, Ischemic Attack, Transient etiology, Male, Middle Aged, Mortality, Multivariate Analysis, Propensity Score, Proportional Hazards Models, Pyrazoles therapeutic use, Pyridones therapeutic use, Rivaroxaban therapeutic use, Stroke epidemiology, Stroke etiology, Warfarin therapeutic use, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Ischemic Attack, Transient prevention & control, Stroke prevention & control
- Abstract
Direct oral anticoagulants (DOACs) have been used in clinical practice in the United States for the last 4 to 6 years. Although DOACs may be an attractive alternative to warfarin in many patients, long-term outcomes of use of these medications are unknown. We performed a propensity-matched analysis to report patient important outcomes of death, stroke/transient ischemic attack (TIA), bleeding, major bleeding, and dementia in patients taking a DOAC or warfarin. Patients receiving long-term anticoagulation from June 2010 to December 2014 for thromboembolism prevention with either warfarin or a DOAC were matched 1:1 by index date and propensity score. Multivariable Cox hazard regression was performed to determine the risk of death, stroke/TIA, major bleed, and dementia by the anticoagulant therapy received. A total of 5,254 patients were studied (2,627 per group). Average age was 72.4 ± 10.9 years, and 59.0% were men. Most patients were receiving long-term anticoagulation for AF management (warfarin: 96.5% vs DOAC: 92.7%, p <0.0001). Rivaroxaban (55.3%) was the most commonly used DOAC, followed by apixaban (22.5%) and dabigatran (22.2%). The use of DOACs compared with warfarin was associated with a reduced risk of long-term adverse outcomes: death (p = 0.09), stroke/TIA (p <0.0001), major bleed (p <0.0001), and bleed (p = 0.14). No significant outcome variance was noted in DOAC-type comparison. In the AF multivariable model patients taking DOAC were 43% less likely to develop stroke/TIA/dementia (hazard ratio 0.57 [CI 0.17, 1.97], p = 0.38) than those taking warfarin. Our community-based results suggest better long-term efficacy and safety of DOACs compared with warfarin. DOAC use was associated with a lower risk of cerebral ischemic events and new-onset dementia., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
27. Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications.
- Author
-
Bunch TJ, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Jacobs V, Mallender C, Osborn JS, Stevens SM, Weiss JP, and Woller SC
- Subjects
- Aged, Aged, 80 and over, Atrial Fibrillation complications, Atrial Fibrillation epidemiology, Dementia epidemiology, Female, Heart Valve Prosthesis, Humans, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Retrospective Studies, Risk Factors, Stroke etiology, Thromboembolism epidemiology, Alzheimer Disease epidemiology, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Dementia, Vascular epidemiology, Stroke prevention & control, Thromboembolism drug therapy, Warfarin therapeutic use
- Abstract
Background: The mechanisms behind the association of atrial fibrillation (AF) and dementia are unknown. We previously found a significantly increased risk of dementia in AF patients taking warfarin with a low percentage of time in therapeutic range. The purpose of this study was to determine the extent to which AF itself increases dementia risk, in addition to long-term anticoagulation exposure., Methods and Results: A total of 10 537 patients anticoagulated with warfarin (target INR 2-3), managed by the Clinical Pharmacist Anticoagulation Service with no history of dementia were included. Warfarin indication was for AF (n=4460), thromboembolism (n=5868), and mechanical heart valve(s) (n=209). Patients in the latter 2 categories were included only if they had no prior history of AF. The primary outcome was dementia. Patients with AF were older and had higher rates of hypertension, diabetes, heart failure, and stroke. AF patients experienced higher rates of total dementia (5.8% versus 1.6%, P<0.0001), Alzheimer disease (2.8% versus 0.9%, P<0.0001), and vascular dementia (1.0% versus 0.2%, P<0.0001). A propensity analysis of 6030 patients was performed to account for baseline demographics differences. Long-term risk of dementia remained significant in AF patients compared with matched non-AF patients (total dementia: hazard ratio [HR]=2.42 [1.85-3.18], P<0.0001; Alzheimer: HR=2.04 [1.40-2.98], P<0.0001; senile: HR=2.46 [1.58-3.86], P<0.0001). Low percent therapeutic range compared with a higher percent therapeutic range was associated with dementia risk in both AF (26-50% versus >75%: HR=2.51, P=0.005) and non-AF groups (≤25% versus >75%: HR=3.92, P<0.0001)., Conclusions: The presence of AF significantly increases risk of dementia, including Alzheimer's disease, compared with matched patients receiving warfarin anticoagulation for other reasons. Quality of anticoagulation management remains an important risk factor for dementia in all patients., (© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Published
- 2016
- Full Text
- View/download PDF
28. A Comparison of Remote Magnetic Irrigated Tip Ablation versus Manual Catheter Irrigated Tip Catheter Ablation With and Without Force Sensing Feedback.
- Author
-
Weiss JP, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, Osborn JS, Mallender C, and Bunch TJ
- Subjects
- Aged, Atrial Fibrillation diagnosis, Cohort Studies, Equipment Design instrumentation, Equipment Design methods, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Robotic Surgical Procedures instrumentation, Stereotaxic Techniques instrumentation, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation instrumentation, Catheter Ablation methods, Magnetic Phenomena, Robotic Surgical Procedures methods
- Abstract
Background: Remote magnetic navigation (RMN) and contact force (CF) sensing technologies have been utilized in an effort to improve safety and efficacy of catheter ablation. A comparative analysis of the relative short- and long-term outcomes of AF patients has not been performed. As such, we comparatively evaluated the safety and efficacy of these technologies., Methods: A total of 627 patients who underwent catheter ablation with either a manual irrigated tip catheter: (312, 49.8%) or by RMN: (315, 50.2%) were included in this single-center cohort study. Patients treated with CF (59) were analyzed separately as well. One- and 3-year endpoints included death, HF hospitalization, stroke, TIA, and atrial flutter or AF recurrence., Results: Age averaged 65.1 ± 10.7 years and 64.1% male. One- and 3-year endpoints of death, HF hospitalization, stroke, TIA, and atrial flutter or AF recurrence were statistically similar between manual and RMN treated groups. Fluoroscopy times were significantly lower in the RMN group compared to the manual ablation group (8.47 ± 0.45 vs. 9.63 ± 4.06 minutes, P < 0.0001). CF guided patients had 1-year recurrence rate of AF/atrial flutter statistically identical to patients treated with RMN (36.8% vs. 38.6%; P = 1.00)., Conclusion: RMN results in outcomes similar to manual navigation. The addition of CF sensing catheters did not improve relative procedural outcome or safety profile in comparison to RMN guided ablation in this large observational study of AF ablation., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
29. The Impact of Age on 5-Year Outcomes After Atrial Fibrillation Catheter Ablation.
- Author
-
Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, Weiss JP, Mallender C, Osborn JS, Anderson JL, and Day JD
- Subjects
- Action Potentials, Age Factors, Aged, Aged, 80 and over, Atrial Fibrillation diagnosis, Atrial Fibrillation mortality, Atrial Fibrillation physiopathology, Atrial Flutter etiology, Chi-Square Distribution, Disease-Free Survival, Female, Heart Failure etiology, Heart Rate, Humans, Male, Middle Aged, Multivariate Analysis, Patient Selection, Proportional Hazards Models, Recurrence, Risk Factors, Stroke etiology, Time Factors, Treatment Outcome, Utah, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Catheter Ablation mortality
- Abstract
Background: Catheter ablation of atrial fibrillation (AF) is an established therapeutic rhythm approach in symptomatic patients. Many studies have shown that age has little to no impact on outcomes during the first year after ablation. However, AF is a disease of aging and age-based substrate for arrhythmia is likely to progress. To this regard, we examined patients with 5-year outcome data following an index AF ablation procedure to define the impact of age on long-term outcomes., Methods: A total of 923 patients that underwent their index AF ablation and had 5 years of follow-up were studied. Patients were followed up for atrial flutter/AF recurrence, heart failure, stroke, death, and cardiac function. Patients were separated and compared in 5 age-based groups (<50, 51-60, 61-70, 71-80, >80)., Results: The average age of the population was 66 ± 11 years and 59% were male. The AF was paroxysmal in 55%, persistent in 27%, and longstanding persistent in 18%. Older patients were more likely female and had higher rates of cardiovascular diseases. For every 10-year increase in age there was a higher multivariate-adjusted risk of atrial flutter/AF recurrence (HR: 1.13, P = 0.01), death (HR:1.91, P < 0.0001), and major adverse cardiac events (HR: 1.09, P = 0.07). Although atrial flutter/AF recurrence rates by age were similar at 1 year, at 5 years, younger patients had significantly lower rates of recurrences., Conclusion: Age significantly impacts outcomes after AF ablation when analyzed with long-term follow-up. These data highlight the progressive nature of AF and the need to consider interventions early., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
30. Adverse Remodeling of the Left Atrium in Patients with Atrial Fibrillation: When Is the Tipping Point in Which Structural Changes Become Permanent?
- Author
-
Bunch TJ and Day JD
- Subjects
- Female, Humans, Male, Adenosine Triphosphatases pharmacology, Atrial Fibrillation physiopathology, Electrophysiologic Techniques, Cardiac, Heart Atria pathology, Pulmonary Veins drug effects
- Published
- 2015
- Full Text
- View/download PDF
31. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
- Author
-
Jacobs V, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Muhlestein JB, Anderson JL, Mallender C, and Bunch TJ
- Subjects
- Aged, Catheter Ablation methods, Female, Follow-Up Studies, Humans, Hypertension diagnosis, Hypertension etiology, Hypertension mortality, Hypertension prevention & control, Male, Middle Aged, Patient Selection, Predictive Value of Tests, Prognosis, Recurrence, Research Design, Risk Assessment methods, Risk Factors, Survival Analysis, Time Factors, Treatment Outcome, United States epidemiology, Anticoagulants therapeutic use, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Heart Failure diagnosis, Heart Failure etiology, Heart Failure mortality, Heart Failure prevention & control, Postoperative Complications diagnosis, Postoperative Complications mortality, Postoperative Complications prevention & control, Stroke diagnosis, Stroke etiology, Stroke mortality, Stroke prevention & control
- Abstract
Background: Risk stratification tools are needed to select the right candidates for catheter ablation of atrial fibrillation (AF). Both the CHADS2 and CHA2DS2-VASc scores have utility in predicting AF-related outcomes and guiding anticoagulation treatment., Objective: We sought to determine whether these risk scores predict long-term outcomes after AF ablation and whether one risk score provides comparatively superior performance., Methods: CHADS2 and CHA2DS2-VASc scores were calculated in 2179 patients who underwent a first ablation procedure for AF enrolled in the Intermountain Heart Collaborative Study. CHADS2 and CHA2DS2-VASc scores were categorized as 0-1, 2-4, and ≥5. Patient outcomes were analyzed over 5 years for AF/atrial flutter recurrence and major adverse cardiovascular events (MACE: composite of death, stroke, and heart failure hospitalization)., Results: The mean age was 65.7 ± 10.5 years, and 61.1% were men. Both scores incrementally predicted risk of AF recurrence, stroke, heart failure, and death at 5 years. Increasing CHADS2 (hazard ratio [HR] 1.19; P < .001) and CHA2DS2-VASc (HR 1.15; P < .0001) scores were both associated with AF/atrial flutter recurrence. The results were similar for MACE where increasing CHADS2 (HR 1.54; P < .0001) and CHA2DS2-VASc (HR 1.32; P < .0001) scores were associated with risk. When CHADS2 and CHA2DS2-VASc scores were modeled together, only CHA2DS2-VASc scores significantly predicted AF recurrence (HR 1.13; P = .001), but both were associated with MACE., Conclusion: Both the CHADS2 and CHA2DS2-VASc scores were excellent in stratifying patients for 5-year outcomes after AF ablation. However, the CHA2DS2-VASc score was superior to the CHADS2 score in predicting AF recurrence and AF-related morbidities., (Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
32. Pulmonary vein isolation for atrial fibrillation in the postpneumonectomy population: a feasibility, safety, and outcomes study.
- Author
-
Kanmanthareddy A, Vallakati A, Reddy Yeruva M, Dixit S, DI Biase L, Mansour M, Boolani H, Gunda S, Bunch TJ, Day JD, Ruskin JN, Buddam A, Koripalli S, Bommana S, Natale A, and Lakkireddy D
- Subjects
- Aged, Atrial Fibrillation diagnosis, Atrial Fibrillation etiology, Atrial Fibrillation physiopathology, Catheter Ablation adverse effects, Electrophysiologic Techniques, Cardiac, Feasibility Studies, Female, Humans, Male, Middle Aged, Phlebography methods, Pulmonary Veins diagnostic imaging, Pulmonary Veins physiopathology, Radiography, Interventional, Retrospective Studies, Tomography, X-Ray Computed, Treatment Outcome, United States, Atrial Fibrillation surgery, Catheter Ablation methods, Pneumonectomy adverse effects, Pulmonary Veins surgery
- Abstract
Background: Pulmonary vein isolation (PVI) of the remnant pulmonary vein (PV) stumps in pneumonectomy patients has not been well characterized., Methods: This is a multicenter observational study of patients with a remnant PV stump after pneumonectomy. Consecutive patients with a history of pneumonectomy and who had undergone RF ablation for drug refractory AF were identified from the AF database at the participating institutions., Results: There were 15 patients in whom pneumonectomy was performed, for resection of tumors in 10, infection in 4, and bullae in 1 patient and who underwent RF ablation for AF. The mean age was 63 ± 7 years. The stumps were from the right lower PV in 5, left upper PV in 5, left lower PV in 3, and right upper PV in 2 patients. All the PV stumps were electrically active with PV potentials and 9 (60%) of them had triggered activity. PVI was performed in 14 and focal isolation in 1 patient. At 1-year follow-up, 80% were free of AF, off of antiarrhythmic medications., Conclusion: PV stumps in AF patients with previous pneumonectomy are electrically active and are frequently the sites of active firing. Isolation of these PV stumps can be accomplished safely and effectively using catheter ablation with no practical concern for PV stenosis or compromising PV stump integrity., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
33. Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction.
- Author
-
Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, Weiss JP, Mallender C, Osborn JS, Anderson JL, and Day JD
- Subjects
- Aged, Aged, 80 and over, Atrial Fibrillation diagnosis, Atrial Fibrillation mortality, Atrial Fibrillation physiopathology, Comorbidity, Disease Progression, Female, Heart Failure mortality, Heart Failure physiopathology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Recovery of Function, Recurrence, Retrospective Studies, Risk Factors, Stroke mortality, Stroke physiopathology, Stroke Volume, Time Factors, Treatment Outcome, Utah epidemiology, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Left mortality, Ventricular Dysfunction, Left physiopathology, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Catheter Ablation mortality, Systole, Ventricular Dysfunction, Left epidemiology, Ventricular Function, Left
- Abstract
Background: Catheter ablation of atrial fibrillation (AF) is an established therapy for symptomatic patients. The long-term efficacy and impact of catheter ablation among patients with severe systolic heart failure (SHF) requires additional study to understand if outcomes achieved at 1 year are maintained and mechanisms of AF recurrence., Methods: Three groups with SHF and 5 years of follow-up were matched 1:4:4 by age (±5 years) and sex: AF ablation patients receiving their first ablation (n = 267), AF patients that did not receive an ablation (n = 1,068), and SHF patient without AF (n = 1,068). SHF was based upon clinical diagnosis and an ejection fraction (EF) ≤35%. Patients were followed for 5-year primary outcomes of AF recurrence, heart failure, stroke, death, and cardiac function., Results: At 5 years, 60.7% of patients had clinical recurrence of AF. Diabetes and a prior heart attack were significant predictors of long-term risk of AF recurrence. Long-term mortality rates were 27%, 55%, 50%, in the AF ablation, AF, and no AF groups, respectively (P < 0.0001), with the lower rates attributed to lower cardiovascular mortality. At 5 years, there was no difference in EF, yet HF hospitalizations were lower following AF ablation compared to patients with AF and no ablation. Stroke rates at 5 years trended to be lower in the AF ablation group, but the difference was not statistically significant., Conclusion: Recurrence rates of AF in patients with SHF after ablation are common at 5 years with an anticipated ongoing increase. Long-term AF-related comorbidities tended to be less in the AF ablation group., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
34. Atrial fibrillation and dementia.
- Author
-
Jacobs V, Cutler MJ, Day JD, and Bunch TJ
- Subjects
- Anticoagulants adverse effects, Atrial Fibrillation drug therapy, Dementia prevention & control, Humans, Hypertension complications, Inflammation complications, Risk Factors, Atrial Fibrillation complications, Dementia etiology
- Abstract
Emerging evidence has shown a consistent association between AF and risk of dementia, including Alzheimer׳s disease. It is likely that a constellation of various mechanisms combine to cause dementia in AF patients. Both AF and dementia share multiple common risk factors, and as such these may be targets of early prevention strategies to reduce risk. In patients with AF, choices regarding type and duration of anticoagulation as well as rhythm- and rate-control strategies can influence dementia risk., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
35. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia.
- Author
-
Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, Crandall BG, Day JD, Johanning K, Long Y, Mallender C, Olson JL, Osborn JS, Weiss JP, and Bunch TJ
- Subjects
- Aged, Aged, 80 and over, Anticoagulants administration & dosage, Anticoagulants adverse effects, Atrial Fibrillation diagnosis, Cohort Studies, Comorbidity, Dementia etiology, Dementia physiopathology, Dose-Response Relationship, Drug, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Severity of Illness Index, Survival Analysis, Time Factors, Treatment Outcome, Warfarin administration & dosage, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Dementia epidemiology, International Normalized Ratio, Warfarin adverse effects
- Abstract
Background: The mechanisms behind the association of atrial fibrillation (AF) and dementia are unknown. One possibility is that exposure to chronic microembolism or microbleeds results in repetitive cerebral injury that is manifest by cognitive decline., Objective: The purpose of this study was to test the hypothesis that AF patients with a low percentage of time in the therapeutic range (TTR) are at higher risk for dementia due to under- or overanticoagulation., Methods: Patients anticoagulated with warfarin (target international normalized ratio [INR] 2-3), managed by the Intermountain Healthcare Clinical Pharmacist Anticoagulation Service with no history of dementia or stroke/transient ischemic attack, were included in the study. The primary outcome was dementia incidence defined by ICD-9 codes. Percent time in TTR was calculated using the method of linear interpolation and stratified as >75%, 51%-75%, 26%-50%, and ≤25%. Multivariable Cox hazard regression was used to determine dementia incidence by percentage categories of TTR., Results: A total of 2605 patients (age 73.7 ± 10.8 years, 1408 [54.0%] male) were studied. The CHADS2 score distribution was 0: 216 (8.3%); 1: 579 (22.2%); 2: 859(33.0%); 3: 708 (27.2%); and ≥4: 243 (9.3%). The percent TTR averaged 63.1 ± 21.3, with percent INR <2.0: 25.6% ± 17.9% and percent INR >3.0: 16.2% ± 13.6%. Dementia was diagnosed in 109 patients (4.2%) (senile: 37 [1.4%]; vascular: 8 [0.3%]; Alzheimer: 64 (2.5%]). After adjustment, decreasing categories of percent TTR were associated with increased dementia risk (vs >75%): <25%: hazard ratio (HR) 5.34, P < .0001; 26%-50%: HR 4.10, P < .0001; and 51%-75%: HR = 2.57, P = .001., Conclusion: Quality of anticoagulation management represented as percent TTR among AF patients without dementia was associated with dementia incidence. These data support the possibility of chronic cerebral injury as a mechanism that underlies the association of AF and dementia., (Copyright © 2014 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
36. Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: multicenter FIRM registry.
- Author
-
Miller JM, Kowal RC, Swarup V, Daubert JP, Daoud EG, Day JD, Ellenbogen KA, Hummel JD, Baykaner T, Krummen DE, Narayan SM, Reddy VY, Shivkumar K, Steinberg JS, and Wheelan KR
- Subjects
- Female, Humans, Male, Middle Aged, Prospective Studies, Registries, Treatment Outcome, Atrial Fibrillation physiopathology, Atrial Fibrillation surgery, Catheter Ablation methods
- Abstract
Introduction: The success of pulmonary vein isolation (PVI) for atrial fibrillation (AF) may be improved if stable AF sources identified by Focal Impulse and Rotor Mapping (FIRM) are also eliminated. The long-term results of this approach are unclear outside the centers where FIRM was developed; thus, we assessed outcomes of FIRM-guided AF ablation in the first cases at 10 experienced centers., Methods: We prospectively enrolled n = 78 consecutive patients (61 ± 10 years) undergoing FIRM guided ablation for persistent (n = 48), longstanding persistent (n = 7), or paroxysmal (n = 23) AF. AF recordings from both atria with a 64-pole basket catheter were analyzed using a novel mapping system (Rhythm View(TM) ; Topera Inc., CA, USA). Identified rotors/focal sources were ablated, followed by PVI., Results: Each institution recruited a median of 6 patients, each of whom showed 2.3 ± 0.9 AF rotors/focal sources in diverse locations. 25.3% of all sources were right atrial (RA), and 50.0% of patients had ≥1 RA source. Ablation of all sources required a total of 16.6 ± 11.7 minutes, followed by PVI. On >1 year follow-up with a 3-month blanking period, 1 patient lost to follow-up (median time to 1st recurrence: 245 days, IQR 145-354), single-procedure freedom from AF was 87.5% (patients without prior ablation; 35/40) and 80.5% (all patients; 62/77) and similar for persistent and paroxysmal AF (P = 0.89)., Conclusions: Elimination of patient-specific AF rotors/focal sources produced freedom-from-AF of ≈80% at 1 year at centers new to FIRM. FIRM-guided ablation has a rapid learning curve, yielding similar results to original FIRM reports in each center's first cases., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
37. The electrophysiologist's new clothes and the cardiac MRI that told the truth.
- Author
-
Bunch TJ and Day JD
- Subjects
- Female, Humans, Male, Atrial Fibrillation therapy, Catheter Ablation, Cicatrix diagnosis, Electrophysiologic Techniques, Cardiac, Heart Atria surgery, Magnetic Resonance Angiography, Pulmonary Veins surgery, Surgery, Computer-Assisted
- Published
- 2014
- Full Text
- View/download PDF
38. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score.
- Author
-
Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, Mallender C, Anderson JL, Muhlestein BJ, Lappe DL, and Day JD
- Subjects
- Aged, Atrial Fibrillation prevention & control, Catheter Ablation, Comorbidity, Female, Heart Failure epidemiology, Humans, Hyperlipidemias epidemiology, Hypertension epidemiology, Male, Middle Aged, Risk Assessment, Risk Factors, Atrial Fibrillation epidemiology, Atrial Fibrillation surgery, Stroke epidemiology
- Abstract
Background: Atrial fibrillation (AF) is a leading cause of total and fatal ischemic stroke. Stroke risk after AF ablation appears to be favorably affected; however, it is largely unknown whether the benefit extends to all stroke CHADS2 risk profiles of AF patients., Objective: To determine if ablation of atrial fibrillation reduces stroke rates in all risk groups., Methods: A total of 4212 consecutive patients who underwent AF ablation were compared (1:4) with 16,848 age-/sex-matched controls with AF (no ablation) and to 16,848 age-/sex-matched controls without AF. Patients were enrolled from the large ongoing prospective Intermountain Atrial Fibrillation Study and were followed for at least 3 years., Results: Of the 37,908 patients, the mean age was 65.0 ± 13 years and 4.4% (no AF), 6.3% (AF, no ablation), and 4.5% (AF ablation) patients had a prior stroke (P < .0001). The profile of CHADS2 scores between comparative groups was similar: 0-1 (69.3%, no AF; 62.3%, AF, no ablation; 63.6%, AF ablation), 2-3 (26.5%, no AF; 29.7%, AF, no ablation; 28.7%, AF ablation), and ≥4 (4.3%, no AF; 8.0%, AF, no ablation; 7.7%, AF ablation). A total of 1296 (3.4%) patients had a stroke over the follow-up period. Across all CHADS2 profiles and ages, AF patients with ablation had a lower long-term risk of stroke compared to patients without ablation. Furthermore, AF ablation patients had similar long-term risks of stroke across all CHADS2 profiles and ages compared to patients with no history of AF., Conclusions: In our study populations, AF ablation patients have a significantly lower risk of stroke compared to AF patients who do not undergo ablation independent of baseline stroke risk score., (Copyright © 2013 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
39. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes.
- Author
-
Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, and Day JD
- Subjects
- Aged, Atrial Fibrillation complications, Atrial Fibrillation mortality, Disease-Free Survival, Female, Heart Failure etiology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Recurrence, Treatment Outcome, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Catheter Ablation, Delayed Diagnosis statistics & numerical data
- Abstract
Background: Many patients who develop atrial fibrillation (AF) will experience a worsening of their arrhythmia over time. The optimal time to proceed with catheter ablation during the disease course is unknown. Further, whether delays in treatment will negatively influence outcomes is unknown., Objective: The purpose of this study was to examine the impact of delay in treatment after the first clinical diagnosis of AF on ablation-related outcomes., Methods: A total of 4535 consecutive patients who underwent an AF ablation procedure that had long-term established care within an integrated health care system were evaluated. Recursive partitioning was used to determine categories associated with changes in risk from the time of first AF diagnosis to first AF ablation: 1: 30-180 (n = 1152), 2: 181-545 (n = 856), 3: 546-1825 (n = 1326), and 4: >1825 (n = 1201) days. Outcomes evaluated include 1-year AF recurrence, stroke, heart failure hospitalization, and death., Results: With increasing time to treatment, surprisingly patients were older (1: 63.7 ± 11.1, 2: 62.6 ± 11.8, 3: 66.4 ± 10.2, 4: 67.6 ± 9.7; P <.0001) and had more hypertension (1: 53.0%, 2: 59.0%, 3: 53.8%, 4: 39.0%; P <.0001). For each strata of time increase, there was a direct increase of 1-year AF recurrence (1: 19.4%, 2: 23.4%, 3: 24.9%, 4: 24.0%: P trend = .02). After adjustment, clinically significant differences in risk of recurrent AF were found when compared to the 30-180 day time category: 181-545: odds ratio (OR) = 1.23, P = .08; 546-1825: OR = 1.27, P = .02; and >1825: OR = 1.25, P = .05. No differences were observed for 1-year stroke among the groups. Death (1: 2.1%, 2: 3.9%, 3: 5.7%, 4: 4.4%: P trend = .001) and heart failure hospitalization (1: 2.6%, 2: 4.1%, 3: 5.4%, 4: 4.4%; P trend = .009) rates at 1 year were higher in the most delayed groups., Conclusion: Delays in treatment with catheter ablation impact procedural success rates independent of temporal changes to the AF subtype at ablation., (Copyright © 2013 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
40. The atrial fibrillation ablation theory of relativity.
- Author
-
Bunch TJ and Day JD
- Subjects
- Female, Humans, Male, Atrial Fibrillation surgery, Cardiac Catheters, Catheter Ablation instrumentation, Echocardiography, Three-Dimensional, Pulmonary Veins surgery, Radiographic Image Interpretation, Computer-Assisted, Surgery, Computer-Assisted instrumentation, Tomography, X-Ray Computed
- Published
- 2013
- Full Text
- View/download PDF
41. Intracardiac ultrasound for esophageal anatomic assessment and localization during left atrial ablation for atrial fibrillation.
- Author
-
Bunch TJ, May HT, Crandall BG, Weiss JP, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Johnson DL, and Day JD
- Subjects
- Aged, Female, Humans, Male, Treatment Outcome, Atrial Fibrillation diagnostic imaging, Atrial Fibrillation surgery, Catheter Ablation methods, Esophagus diagnostic imaging, Imaging, Three-Dimensional methods, Surgery, Computer-Assisted methods, Ultrasonography methods
- Abstract
Background: Esophageal injury during left atrial ablation is associated with a significant risk of mortality and morbidity. There are no validated approaches to reduce injury outside of avoidance, a strategy critically dependent on a precise understanding of the esophageal anatomy and location. Intracardiac ultrasound (ICE) can provide a real-time assessment of the esophagus during ablation. We hypothesized that ICE can accurately define esophageal anatomy and location to enhance avoidance strategies during ablation., Methods: Fifty patients underwent atrial fibrillation (AF) ablation. The left atrium and pulmonary vein anatomies were rendered by traditional electroanatomic mapping (CARTO). A Navistar catheter within the esophagus was used to create a traditional electroanatomic esophageal anatomy. ICE imaging was used to create a second geometry of the esophagus. The traditional and ICE anatomies of the esophagus were compared and the greatest border dimensions used to avoid injury., Results: The average age was 66 ± 10 years, 45% had persistent/longstanding persistent AF, and 18% had a prior AF ablation. The esophagus location was leftward in 17 (34%), midline in 22 (44%), and rightward in 11 (22%). Traditional esophagus and ICE imaging correlated within 1 cm in the greatest distance in 26 (52%) patients. Traditional imaging underestimated the esophageal location by >1-1.5 cm in 9 (18%) and >1.5 cm in 15 (30%). In those with poor correlation (>1.5 cm), the most common cause was the presence of a hiatal hernia. Ablation energy delivery was performed outside the greatest esophagus anatomy borders. Of those with 12-month follow-up, 75% were AF/atrial flutter free without antiarrhythmic drugs. No esophageal injuries were observed. One patient experienced a TIA greater than 6 months postablation., Conclusion: These data demonstrate that traditional means of mapping the esophagus using a catheter within the esophagus are insufficient and often grossly underestimate the actual anatomy. Imaging techniques that define the complete esophageal lumen should be considered to truly minimize esophageal injury risk., (© 2012 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
42. Atrial fibrillation and atrial flutter: nonpharmacologic therapy.
- Author
-
Johnson DL, Day JD, Doty JR, and Bunch TJ
- Subjects
- Adult, Age Factors, Aged, Atrial Fibrillation physiopathology, Atrial Flutter physiopathology, Humans, Treatment Outcome, Atrial Fibrillation surgery, Atrial Flutter surgery, Catheter Ablation methods
- Abstract
As elderly patients present significant challenges for long-term pharmacologic management, nonpharmacologic treatment of atrial fibrillation (AF) will continue to be a vital option in improving the quality of life and function of these patients. This review discusses nonpharmacologic approaches for AF in the elderly. Observational studies of catheter ablation suggest similar long-term efficacy and safety rates in elderly and younger groups. Minimally invasive surgical approaches have distinct advantages in certain populations. Further research, adequately powered to assess age-related differences, is needed to confirm the findings of observational studies of elderly patients who have undergone nonpharmacologic approaches to rhythm control., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
43. Phrenic nerve pacing during atrial ablation: a stimulus plan that works.
- Author
-
Bunch TJ and Day JD
- Subjects
- Female, Humans, Male, Atrial Fibrillation surgery, Cardiac Pacing, Artificial methods, Catheter Ablation adverse effects, Peripheral Nerve Injuries diagnosis, Peripheral Nerve Injuries prevention & control, Phrenic Nerve injuries
- Published
- 2012
- Full Text
- View/download PDF
44. Examining the risks and benefits of transesophageal echocardiogram imaging during catheter ablation for atrial fibrillation.
- Author
-
Bunch TJ and Day JD
- Subjects
- Female, Humans, Male, Atrial Fibrillation surgery, Catheter Ablation, Echocardiography, Transesophageal adverse effects, Esophageal Diseases epidemiology, Esophagus injuries, Hematoma epidemiology
- Published
- 2012
- Full Text
- View/download PDF
45. Achieving favorable very long-term outcomes after catheter ablation for atrial fibrillation: an exciting adventure or delusional quest?
- Author
-
Bunch TJ and Day JD
- Subjects
- Female, Humans, Male, Atrial Fibrillation surgery, Catheter Ablation, Pulmonary Veins surgery
- Published
- 2011
- Full Text
- View/download PDF
46. Atrial fibrillation hospitalization is not increased with short-term elevations in exposure to fine particulate air pollution.
- Author
-
Bunch TJ, Horne BD, Asirvatham SJ, Day JD, Crandall BG, Weiss JP, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, and Pope CA 3rd
- Subjects
- Adult, Aged, Aged, 80 and over, Environmental Exposure analysis, Female, Humans, Male, Middle Aged, Prevalence, Risk Assessment, Risk Factors, Utah epidemiology, Altitude, Atrial Fibrillation epidemiology, Environmental Exposure statistics & numerical data, Hospitalization statistics & numerical data, Particulate Matter analysis
- Abstract
Background: Previous studies have observed that short-term exposure to elevated concentrations of particulate matter (PM) air pollution increases risk of acute ischemic heart disease events and heart failure hospitalization, alters cardiac autonomic function, and increases risk of arrhythmias. This study explored the potential associations between short-term elevations in PM exposure and atrial fibrillation (AF)., Methods and Results: A case-crossover study design was used to explore associations between fine PM (PM2.5, particles with an aerodynamic diameter ≤2.5 μm) and 10,457 AF hospitalizations from 1993 to 2008 of patients who lived on Utah’s Wasatch Front. Patients were hospitalized at Intermountain Healthcare facilities with a primary diagnosis of AF. Concurrent day exposure and cumulative lagged exposures for up to 21 days were explored and the data were stratified by sex, age, and previous or subsequent admission for myocardial infarction. Although the estimated associations between PM2.5 and AF hospitalizations for the various lag structures and strata were consistently positive suggestive of risk, they were not statistically significant and they were extremely small compared to previously observed associations with ischemic heart disease events and heart failure hospitalizations. Further, we observed no additive risk between PM2.5 and AF hospitalization in those with respiratory disease or sleep apnea., Conclusions: Unlike previously observed associations with ischemic heart disease events and heart failure hospitalizations using similar study design and approaches, this study found that hospitalization for AF was not significantly associated with elevations in short-term exposure to fine PM air pollution.
- Published
- 2011
- Full Text
- View/download PDF
47. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation.
- Author
-
Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, and Day JD
- Subjects
- Aged, Atrial Fibrillation mortality, Catheter Ablation mortality, Cohort Studies, Dementia mortality, Female, Humans, Male, Middle Aged, Mortality trends, Prospective Studies, Stroke mortality, Time Factors, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation trends, Dementia surgery, Stroke surgery
- Abstract
Introduction: Atrial fibrillation (AF) adversely impacts mortality, stroke, heart failure, and dementia. AF ablation eliminates AF in most patients. We evaluated the long-term impact of AF ablation on mortality, heart failure (HF), stroke, and dementia in a large system-wide patient population., Methods: A total of 4,212 consecutive patients who underwent AF ablation were compared (1:4) to 16,848 age/gender matched controls with AF (no ablation) and 16,848 age/gender matched controls without AF. Patients were enrolled from the large ongoing prospective Intermountain AF study and were followed for at least 3 years., Results: Of the 37,908 patients, mean age 65.0 ± 13 years, 5,667 (14.9%) died, 1,296 (3.4%) had a stroke, and 1,096 (2.9%) were hospitalized for HF over >3 years of follow-up. AF ablation patients were less likely to have diabetes, but were more likely to have hypertension, HF, and significant valvular heart disease. AF ablation patients had a lower risk of death and stroke in comparison to AF patients without ablation. Alzheimer's dementia occurred in 0.2% of the AF ablation patients compared to 0.9% of the AF no ablation patients and 0.5% of the no AF patients (P < 0.0001). Other forms of dementia were also reduced significantly in those treated with ablation. Compared to patients with no AF, AF ablation patients had similar long-term rates of death, dementia, and stroke., Conclusions: AF ablation patients have a significantly lower risk of death, stroke, and dementia in comparison to AF patients without ablation. AF ablation may eliminate the increased risk of death and stroke associated with AF., (© 2011 Wiley Periodicals, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
48. A strategy of rapid cardioversion minimizes the significance of early recurrent atrial tachyarrhythmias after ablation for atrial fibrillation.
- Author
-
Malasana G, Day JD, Weiss JP, Crandall BG, Bair TL, May HT, Osborn JS, Anderson JL, Muhlestein JB, Lappe DL, Nelson J, and Bunch TJ
- Subjects
- Aged, Databases, Factual, Electric Countershock adverse effects, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Registries, Secondary Prevention, Tachycardia epidemiology, Tachycardia etiology, Time Factors, Atrial Fibrillation physiopathology, Atrial Fibrillation therapy, Electric Countershock methods, Tachycardia physiopathology
- Abstract
Background: The significance of early recurrent atrial tachyarrhythmias after atrial fibrillation (AF) ablation is unclear. Atrial remodeling driven by these tachyarrhythmias can result in electrical, contractile, and structural changes that may impair long-term therapy success. Aggressive attempts to restore sinus rhythm in the temporal period of healing after ablation might improve outcomes., Methods: A total of 1,759 AF ablations were performed at Intermountain Medical Center or LDS Hospital. A total of 455 of those were among patients requiring repeat ablations. Patients were instructed to take their pulse daily and, if greater than 100 bpm or irregular, present the following business day fasting to the clinic for evaluation and cardioversion if AF or atrial flutter (AFL) were present., Results: Of the ablations performed, a total of 515 (29%, age: 65.6 ± 11.2 years, male: 57.9%) developed AF/AFL that required cardioverison. The majority of these arrhythmias first occurred in the initial 90 days (63.7%) postablation. During this period, 62.8% were on an antiarrhythmic drug (AAD). Only 25.1% were using an AAD at 3 months. The majority of ablations (75.6%) who experienced AF/AFL within the first 90 days after ablation were in sinus rhythm with no AAD at 1 year. Further, 48% of those with the first recurrence from 90 to 180 days were in sinus rhythm with no AAD at 1 year., Conclusions: The time at which the first recurrence of AF/AFL occurs impacts long-term outcomes. An aggressive strategy of rapid cardioversion postablation reduces the significance of recurrent AF/AFL during the first 6 months., (© 2011 Wiley Periodicals, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
49. Radiofrequency ablation of atrial fibrillation in patients with mitral or aortic mechanical prosthetic valves: a feasibility, safety, and efficacy study.
- Author
-
Lakkireddy D, Nagarajan D, Di Biase L, Vanga SR, Mahapatra S, Jared Bunch T, Day JD, Burkhardt DJ, Umbarger L, Dendi R, Pimentel R, Berenbom L, Emert M, Gerken A, Bommana S, Ray W, Atkins D, Murray C, Dawn B, and Natale A
- Subjects
- Atrial Fibrillation etiology, Atrial Fibrillation physiopathology, Electrocardiography, Ambulatory, Feasibility Studies, Female, Follow-Up Studies, Heart Conduction System physiopathology, Heart Conduction System surgery, Heart Valve Diseases physiopathology, Heart Valve Diseases surgery, Humans, Imaging, Three-Dimensional, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Aortic Valve, Atrial Fibrillation surgery, Catheter Ablation methods, Heart Rate physiology, Heart Valve Diseases complications, Heart Valve Prosthesis, Mitral Valve
- Abstract
Background: Patients with prosthetic valves have a high prevalence of atrial fibrillation (AF). We report a multicenter experience of performing pulmonary vein antral isolation (PVAI) in this challenging, high-risk cohort of patients., Objective: The purpose of this study was to assess the feasibility, safety, and efficacy of radiofrequency (RF) ablation for sinus rhythm restoration in AF patients with mitral or aortic mechanical prosthetic valves., Methods: A total of 50 patients with prosthetic valves (group I) who underwent RF ablation for AF between January 1, 2007, and April 30, 2009, were identified prospectively at four tertiary care centers. A matched group of 50 patients (group II) acted as controls., Results: Total procedural time (199.4 ± 49 minutes vs 166.6 ± 27.5 minutes, P <.001) and fluoroscopy time (60 ± 17 minutes vs 53.8 ± 6.8 minutes, P <.01) were prolonged, with a higher incidence of atrial flutter at 3 months in group I (18% vs 6%, P = .1) compared to group II. At 12 months, 80% of patients in the valve group were in sinus rhythm after an average of 1.3 procedures, and 82% of controls were in sinus rhythm after an average 1.2 procedures (P = .9). There was a trend toward a higher nonfatal complication rate in the valve group than in the control group (8% vs 4%, P = .1)., Conclusion: In patients with prosthetic valves, RF ablation for AF is feasible, safe, and efficacious, with a trend toward a higher nonfatal complication rate and an increased rate of postablation atrial flutter., (Copyright © 2011. Published by Elsevier Inc.)
- Published
- 2011
- Full Text
- View/download PDF
50. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia.
- Author
-
Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, Anderson JL, Muhlestein JB, Horne BD, Lappe DL, and Day JD
- Subjects
- Adult, Aged, Alzheimer Disease mortality, Atrial Fibrillation mortality, Dementia, Vascular mortality, Female, Humans, Male, Middle Aged, Risk Factors, Alzheimer Disease complications, Atrial Fibrillation complications, Dementia, Vascular complications
- Abstract
Background: The aging population has resulted in more patients living with cardiovascular disease, such as atrial fibrillation (AF). Recent focus has been placed on understanding the long-term consequences of chronic cardiovascular disease, such as a potential increased risk of dementia., Objective: This study sought to determine whether there is an association between AF and dementia and whether their coexistence is an independent marker of risk., Methods: A total of 37,025 consecutive patients from the large ongoing prospective Intermountain Heart Collaborative Study database were evaluated and followed up for a mean of 5 years for the development of AF and dementia. Dementia was sub-typed into vascular (VD), senile (SD), Alzheimer's (AD), and nonspecified (ND)., Results: Of the 37,025 patients with a mean age of 60.6 +/- 17.9 years, 10,161 (27%) developed AF and 1,535 (4.1%) developed dementia (179 VD, 321 SD, 347 AD, 688 ND) during the 5-year follow-up. Patients with dementia were older and had higher rates of hypertension, coronary artery disease, renal failure, heart failure, and prior strokes. In age-based analysis, AF independently was significantly associated with all dementia types. The highest risk was in the younger group (<70). After dementia diagnosis, the presence of AF was associated with a marked increased risk of mortality (VD: hazard ratio [HR] = 1.38, P = .01; SD: HR = 1.41, P = .001; AD: HR = 1.45; ND: HR = 1.38, P <.0001)., Conclusion: AF was independently associated with all forms of dementia. Although dementia is strongly associated with aging, the highest risk of AD was in the younger group, in support of the observed association. The presence of AF also identified dementia patients at high risk of death., (Copyright 2010 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.